{"title":"Retroviruses: HIV, HTLV \u0026 HERV","description":null,"products":[{"product_id":"herm-1811","title":"Anti-Human Endogenous Retrovirus Type K (HERV K) Envelope Protein, IgG Fraction, Monoclonal","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 2I5\/H4) obtained by immunization of mice with HERV K envelope antigen (79.5 kDa). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1:8,000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Toenjes, R.R. et al. (1997) Virology 233, 280 - 291.\u003cbr\u003e2. Barbulescu, M. et al. (1999) Curr. Biol. 9, 861 - 868.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-herm-1811\"\u003ePublications using Austral Biologicals HERM-1811-5\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report experimental use of HERM-1811:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-2437\" rel=\"noopener\" target=\"_blank\"\u003eTargeting DOT1L Reactivates HERV-K to Drive Cell-Autonomous and Paracrine Senescence in Adenocarcinoma of the Esophagogastric Junction\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFeng et al., Cancer Research 86(14):3588-3603 (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.074845\" rel=\"noopener\" target=\"_blank\"\u003eAn Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eXiong et al., Circulation 152(13):939-956 (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1126\/sciadv.ady8168\" rel=\"noopener\" target=\"_blank\"\u003eHuman endogenous retrovirus K (HERV-K) envelope structures in pre- and postfusion by cryo-EM\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eShek et al., Science Advances 11(35):eady8168 (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1093\/procel\/pwaf025\" rel=\"noopener\" target=\"_blank\"\u003eSingle-nucleus transcriptomics decodes the link between aging and lumbar disc herniation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Protein \u0026amp; Cell 16(8):667-684 (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cell.2022.12.017\" rel=\"noopener\" target=\"_blank\"\u003eResurrection of endogenous retroviruses during aging reinforces senescence\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLiu et al., Cell 186(2):287-304.e26 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1164\/rccm.202102-0446OC\" rel=\"noopener\" target=\"_blank\"\u003eEndogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTaylor et al., American Journal of Respiratory and Critical Care Medicine 206(8):1019-1034 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3857\" rel=\"noopener\" target=\"_blank\"\u003eHuman Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMaze et al., Cancer Research 82(2):235-247 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms222212398\" rel=\"noopener\" target=\"_blank\"\u003eA Comprehensive Analysis of Human Endogenous Retroviruses HERV-K (HML.2) from Teratocarcinoma Cell Lines and Detection of Viral Cargo in Microvesicles\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMorozov and Morozov, International Journal of Molecular Sciences 22(22):12398 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.5483\/BMBRep.2021.54.7.246\" rel=\"noopener\" target=\"_blank\"\u003eExpression profiles of human endogenous retrovirus (HERV)-K and HERV-R Env proteins in various cancers\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKo et al., BMB Reports 54(7):368-373 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/s13100-020-0204-1\" rel=\"noopener\" target=\"_blank\"\u003eCharacterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTatkiewicz et al., Mobile DNA 11:9 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms21217855\" rel=\"noopener\" target=\"_blank\"\u003eFormation of HERV-K and HERV-Fc1 Envelope Family Members is Suppressed on Transcriptional and Translational Level\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGröger et al., International Journal of Molecular Sciences 21(21):7855 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.2005237117\" rel=\"noopener\" target=\"_blank\"\u003ePosttranscriptional regulation of human endogenous retroviruses by RNA-binding motif protein 4, RBM4\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eForoushani et al., Proceedings of the National Academy of Sciences 117(42):26520-26530 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1126\/sciadv.aba3200\" rel=\"noopener\" target=\"_blank\"\u003ePrimate-restricted KRAB zinc finger proteins and target retrotransposons control gene expression in human neurons\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTurelli et al., Science Advances 6(35):eaba3200 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1073\/pnas.2002427117\" rel=\"noopener\" target=\"_blank\"\u003eRegulation of stem cell function and neuronal differentiation by HERV-K via mTOR pathway\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eWang et al., Proceedings of the National Academy of Sciences 117(30):17842-17853 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/v10080412\" rel=\"noopener\" target=\"_blank\"\u003eDisruption by SaCas9 Endonuclease of HERV-K env, a Retroviral Gene with Oncogenic and Neuropathogenic Potential, Inhibits Molecules Involved in Cancer and Amyotrophic Lateral Sclerosis\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eIbba et al., Viruses 10(8):412 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1007123\" rel=\"noopener\" target=\"_blank\"\u003eReconstruction of the cell entry pathway of an extinct virus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRobinson-McCarthy et al., PLOS Pathogens 14(8):e1007123 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.7554\/eLife.35989\" rel=\"noopener\" target=\"_blank\"\u003eSystematic perturbation of retroviral LTRs reveals widespread long-range effects on human gene regulation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFuentes et al., eLife 7:e35989 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/s13024-018-0275-3\" rel=\"noopener\" target=\"_blank\"\u003eTranscriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMayer et al., Molecular Neurodegeneration 13(1):39 (2018).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.virol.2017.06.004\" rel=\"noopener\" target=\"_blank\"\u003eExpression of HERV-K108 envelope interferes with HIV-1 production\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eTerry et al., Virology 509:52-59 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.03136-15\" rel=\"noopener\" target=\"_blank\"\u003eInfectious Entry Pathway Mediated by the Human Endogenous Retrovirus K Envelope Protein\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eRobinson and Whelan, Journal of Virology 90(7):3640-3649 (2016).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.00544-15\" rel=\"noopener\" target=\"_blank\"\u003eHuman Endogenous Retrovirus Type K (HERV-K) Particles Package and Transmit HERV-K-Related Sequences\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eContreras-Galindo et al., Journal of Virology 89(14):7187-7201 (2015).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4049\/jimmunol.1302108\" rel=\"noopener\" target=\"_blank\"\u003eCutting edge: An antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1-infected cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMichaud et al., Journal of Immunology 193(4):1544-1548 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.00669-14\" rel=\"noopener\" target=\"_blank\"\u003eHIV-1 interacts with human endogenous retrovirus K (HML-2) envelopes derived from human primary lymphocytes\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBrinzevich et al., Journal of Virology 88(11):6213-6223 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/1742-4690-11-10\" rel=\"noopener\" target=\"_blank\"\u003eTrans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMichaud et al., Retrovirology 11:10 (2014).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4103\/1477-3163.109032\" rel=\"noopener\" target=\"_blank\"\u003eHuman endogenous retroviral K element encodes fusogenic activity in melanoma cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Journal of Carcinogenesis 12:5 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.pone.0072756\" rel=\"noopener\" target=\"_blank\"\u003eVaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKraus et al., PLOS ONE 8(8):e72756 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.00602-11\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eContreras-Galindo et al., Journal of Virology 86(1):262-276 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI64560\" rel=\"noopener\" target=\"_blank\"\u003eHERV-K-specific T cells eliminate diverse HIV-1\/2 and SIV primary isolates\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJones et al., Journal of Clinical Investigation 122(12):4473-4489 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4049\/jimmunol.1200079\" rel=\"noopener\" target=\"_blank\"\u003eVaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSacha et al., Journal of Immunology 189(3):1467-1479 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.jri.2011.06.102\" rel=\"noopener\" target=\"_blank\"\u003eHuman endogenous retrovirus K (HERV-K) is expressed in villous and extravillous cytotrophoblast cells of the human placenta\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKämmerer et al., Journal of Reproductive Immunology 91(1-2):1-8 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.01368-09\" rel=\"noopener\" target=\"_blank\"\u003eReconstitution of the ancestral glycoprotein of human endogenous retrovirus K and modulation of its functional activity by truncation of the cytoplasmic domain\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHanke et al., Journal of Virology 83(24):12790-12800 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.yexcr.2008.12.023\" rel=\"noopener\" target=\"_blank\"\u003eThe activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSerafino et al., Experimental Cell Research 315(5):849-862 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.00646-08\" rel=\"noopener\" target=\"_blank\"\u003eHuman Endogenous Retrovirus K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eContreras-Galindo et al., Journal of Virology 82(19):9329-9336 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HERM-1811_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876119342,"sku":"HERM-1811-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-herm-1811-100ug.png?v=1788008512"},{"product_id":"herm-1821","title":"Anti-Human Endogenous Retrovirus Type K (HERV K) Envelope Protein, IgG Fraction, Monoclonal","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 6B7\/I4) obtained by immunization of mice with HERV K envelope antigen (42.8 kDa). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1:2,000 dilution)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Toenjes, R.R. et al. (1997) Virology 233, 280 - 291.\u003cbr\u003eBarbulescu, M. et al. (1999) Curr. Biol. 9, 861 - 868.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-herm-1821\"\u003ePublications using Austral Biologicals HERM-1821-5\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report experimental use of HERM-1821-5:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41467-023-36649-z\" rel=\"noopener\" target=\"_blank\"\u003eEndogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback driving intercellular spread of Drosophila neurodegeneration\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eChang and Dubnau, Nature Communications 14(1):966 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms21217855\" rel=\"noopener\" target=\"_blank\"\u003eFormation of HERV-K and HERV-Fc1 Envelope Family Members is Suppressed on Transcriptional and Translational Level\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGröger et al., International Journal of Molecular Sciences 21(21):7855 (2020).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.4103\/1477-3163.109032\" rel=\"noopener\" target=\"_blank\"\u003eHuman endogenous retroviral K element encodes fusogenic activity in melanoma cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHuang et al., Journal of Carcinogenesis 12:5 (2013).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HERM-1821_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876152110,"sku":"HERM-1821-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-herm-1821-100ug.png?v=1788008642"},{"product_id":"herm-1831","title":"Anti-Human Endogenous Retrovirus Type K (HERV K) Capsid Protein, IgG Fraction,  Monoclonal, Clone 3E11\/I8","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 3E11\/I8) obtained by immunization of mice with HERV K capsid antigen (74 kDa). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1:8,000 dilution) and Western Blot analysis (1:10,000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Toenjes, R.R. et al. (1997) Virology 233, 280 - 291.\u003cbr\u003e2. Barbulescu, M. et al. (1999) Curr. Biol. 9, 861 - 868.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-herm-1831\"\u003ePublications using Austral Biologicals HERM-1831-5\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report experimental use of HERM-1831-5:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1111\/acel.70352\" rel=\"noopener\" target=\"_blank\"\u003eA Novel Human Cellular System for Studying Normal Aging and for Anti-Aging Discovery\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eFeng et al., Aging Cell 25(2):e70352 (2026).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3389\/fmicb.2025.1604022\" rel=\"noopener\" target=\"_blank\"\u003eActivation of human endogenous retroviruses by Sox proteins induces cell apoptosis via the caspase-3 pathway\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eHossain et al., Frontiers in Microbiology 16:1604022 (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cell.2023.01.011\" rel=\"noopener\" target=\"_blank\"\u003eBat pluripotent stem cells reveal unusual entanglement between host and viruses\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDéjosez et al., Cell 186(5):957-974.e28 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.7759\/cureus.26525\" rel=\"noopener\" target=\"_blank\"\u003eDolutegravir Inhibits Proliferation and Motility of BT-20 Tumor Cells Through Inhibition of Human Endogenous Retrovirus Type K\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLi et al., Cureus 14(7):e26525 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/s12977-017-0351-8\" rel=\"noopener\" target=\"_blank\"\u003eMolecular mechanisms by which HERV-K Gag interferes with HIV-1 Gag assembly and particle infectivity\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMonde et al., Retrovirology 14(1):27 (2017).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.07215-11\" rel=\"noopener\" target=\"_blank\"\u003eExpression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGonzalez-Hernandez et al., Journal of Virology 86(15):7790-7805 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.00301-12\" rel=\"noopener\" target=\"_blank\"\u003eHuman endogenous retrovirus K Gag coassembles with HIV-1 Gag and reduces the release efficiency and infectivity of HIV-1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMonde et al., Journal of Virology 86(20):11194-11208 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/1750-1326-6-44\" rel=\"noopener\" target=\"_blank\"\u003eBovine spongiform encephalopathy infection alters endogenous retrovirus expression in distinct brain regions of cynomolgus macaques (Macaca fascicularis)\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGreenwood et al., Molecular Neurodegeneration 6(1):44 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HERM-1831_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876184878,"sku":"HERM-1831-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-herm-1831-100ug.png?v=1788008495"},{"product_id":"herm-1841","title":"Anti-Human Endogenous Retrovirus Type K (HERV K) Gag Protein, IgG Fraction, Monoclonal","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 4D4\/F7) obtained by immunization of mice with HERV K gag antigen (82 kDa). The monoclonal antibody was purified using Protein G-Sepharose.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1:2,000 dilution) and Western Blot analysis (1:8,000 dilution). It recognizes HERV K gag and capsid antigens by Western Blot.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in PBS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1. Toenjes, R.R. et al. (1997) Virology 233, 280 - 291.\u003cbr\u003e2. Barbulescu, M. et al. (1999) Curr. Biol. 9, 861 - 868.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-herm-1841\"\u003ePublications using Austral Biologicals HERM-1841-5\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report experimental use of HERM-1841-5:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1136\/jitc-2024-010099\" rel=\"noopener\" target=\"_blank\"\u003eHERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eBonaventura et al., Journal for ImmunoTherapy of Cancer 13(8):e010099 (2025).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1038\/s41467-023-40786-w\" rel=\"noopener\" target=\"_blank\"\u003eMolecular architecture and conservation of an immature human endogenous retrovirus\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eKrebs et al., Nature Communications 14(1):5149 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cell.2022.12.017\" rel=\"noopener\" target=\"_blank\"\u003eResurrection of endogenous retroviruses during aging reinforces senescence\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLiu et al., Cell 186(2):287-304.e26 (2023).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3857\" rel=\"noopener\" target=\"_blank\"\u003eHuman Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eMaze et al., Cancer Research 82(2):235-247 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.00602-11\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of Human Endogenous Retroviral Elements in the Blood of HIV-1-Infected Individuals\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eContreras-Galindo et al., Journal of Virology 86(1):262-276 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.07215-11\" rel=\"noopener\" target=\"_blank\"\u003eExpression of Human Endogenous Retrovirus Type K (HML-2) Is Activated by the Tat Protein of HIV-1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGonzalez-Hernandez et al., Journal of Virology 86(15):7790-7805 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1172\/JCI64560\" rel=\"noopener\" target=\"_blank\"\u003eHERV-K-specific T cells eliminate diverse HIV-1\/2 and SIV primary isolates\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJones et al., Journal of Clinical Investigation 122(12):4473-4489 (2012).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1186\/1742-4690-8-30\" rel=\"noopener\" target=\"_blank\"\u003eIdentification of the protease cleavage sites in a reconstituted Gag polyprotein of an HERV-K(HML-2) element\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eGeorge et al., Retrovirology 8:30 (2011).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.3109\/07357907.2010.512604\" rel=\"noopener\" target=\"_blank\"\u003eExpression of HERV-K correlates with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLi et al., Cancer Investigation 28(10):1031-1037 (2010).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/JVI.00646-08\" rel=\"noopener\" target=\"_blank\"\u003eHuman Endogenous Retrovirus K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eContreras-Galindo et al., Journal of Virology 82(19):9329-9336 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HERM-1841_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876217646,"sku":"HERM-1841-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-herm-1841-100ug.png?v=1788008495"},{"product_id":"hi1a-610","title":"HIV-1 envelope 101 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion with human superoxide dismutase (SOD). It covers from Ala 548 to Leu 767 of the HIV-1 (SF2 isolate) envelope protein. The apparent MW is 41,700. It has been purified by differential extraction followed by gel filtration chromatography.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 41.7 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in PBS, 20mM DTT, 0.1% SDS, 2mM EDTA (pH 7.4)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Sanchez-Pescador et al., Science 227, 484-492 (1985).\u003cbr\u003e2. Expression of heterologous gene proteins in yeast. S. Pichuantes, A.T. Nguyen and A. Franzusoff. In Protein Engineering: Principles and Practices. J.E. Clealand \u0026amp; C.S Craik Editors, pp. 129-161 (1996)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1A-610_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876250414,"sku":"HI1A-610-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876283182,"sku":"HI1A-610-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1a-610-50ug.png?v=1788008491"},{"product_id":"hi1a-620","title":"HIV-1 envelope 131 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion with human superoxide dismutase (SOD). It covers from Val 473 to Leu 668 (D Ala 518 to Val 546) of the HIV-1 (SF-2 isolate) envelope protein. The apparent MW is 35,600. It has been purified by differential extraction followed by gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 35.6 Kda\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in PBS, 10mM EDTA, 0.1% SDS, 1mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). R. Sanchez-Pescador et al. Science 227, 484-492 (1985)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1A-620_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876315950,"sku":"HI1A-620-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876348718,"sku":"HI1A-620-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1a-620-50ug.png?v=1788008478"},{"product_id":"hi1a-700","title":"HIV-1 envelope p31 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase (SOD). It covers Met 737 to Asp 1003 of the HIV-1 envelope protein (SF-2 isolate). It has been purified by differential extraction and gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 46 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 85% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in PBS, 10mM DTT, 0.1% SDS, 2mM EDTA (pH 7.3)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). R. Sanchez-Pescador et al. Science 227, 484-492 (1985)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1A-700_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876381486,"sku":"HI1A-700-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876414254,"sku":"HI1A-700-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1a-700-50ug.png?v=1788008600"},{"product_id":"hi1a-710","title":"HIV-1 gag p17 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells. It covers Met 5 to Tyr 138 of the HIV-1 gag protein (SF-2 isolate). The apparent MW is 14,900. It has been purified by ion exchange chromatography and gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 14.9 Kda\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS, 1mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e 1. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). R. Sanchez-Pescador et al. Science 227, 484-492 (1985).\u003cbr\u003e2. Expression of heterologous gene proteins in yeast. S. Pichuantes, A.T. Nguyen and A. Franzusoff. In Protein Engineering: Principles and Practices. J.E. Clealand \u0026amp; C.S. Craik Editors, pp. 129-161 (1996).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1A-710_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876447022,"sku":"HI1A-710-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876479790,"sku":"HI1A-710-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1a-710-50ug.png?v=1788008600"},{"product_id":"hi1a-720","title":"HIV-1 Gag p24 Antigen, Recombinant","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells. It covers from Pro 139 to Leu 369 of the HIV-1 gag protein (SF-2 isolate) . It has been purified by ion-exchange chromatography followed by gel filtration.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 27 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in 30mM Tris-HCl, 1mM EDTA (pH 9.0)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003c\/strong\u003e1. Nucleotide sequence and expression of an AIDS,-associated retrovirus (ARV-2). R. Sanchez-Pescador et al. Science 227, 484-492 (1985).\u003cbr\u003e2. Expression of heterologous gene proteins in yeast. S. Pichuantes, A.T. Nguyen and A. Franzusoff. In Protein Engineering: Principles and Practices. J.E. Clealand \u0026amp; C.S. Craik Editors, pp. 129-161 (1996).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hi1a-720\"\u003ePublications using HI1A-720\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of Austral Biologicals HIV-1 p24 antigen:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1080\/15548627.2021.1972403\" rel=\"noopener\" target=\"_blank\"\u003eAutophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLoucif et al., Autophagy 18(6):1256-1273 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.022\" rel=\"noopener\" target=\"_blank\"\u003eImmunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eCapone et al., Mol Ther 29(8):2412-2423 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1080\/15548627.2021.1874134\" rel=\"noopener\" target=\"_blank\"\u003eLipophagy confers a key metabolic advantage that ensures protective CD8A T-cell responses against HIV-1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLoucif et al., Autophagy 17(11):3408-3423 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.76.14.6987-6999.2002\" rel=\"noopener\" target=\"_blank\"\u003eCharacterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eVenturini et al., J Virol 76(14):6987-6999 (2002).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/cdli.9.3.525-529.2002\" rel=\"noopener\" target=\"_blank\"\u003eComparison of human immunodeficiency virus antigens as stimulants for lymphocyte proliferation assays\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eSchmitz et al., Clin Diagn Lab Immunol 9(3):525-529 (2002).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1A-720_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876512558,"sku":"HI1A-720-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876545326,"sku":"HI1A-720-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1a-720-50ug.png?v=1788008599"},{"product_id":"hi1a-730","title":"HIV-1 Gag p55 Antigen, Recombinant","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells. It covers from (equivalent) Met 1 to Gln 502 of the HIV-1 gag protein (SF-2 isolate). The apparent MW is 56,000 Daltons; pI=9.8. It has been purified by ion exchange chromatography, followed by gel filtration.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Stable at least one year at –20°C\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.5 mg\/mL in 50 mM NaPhosphate, 0.4 M NaCl, 6M Urea, pH 7.9.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e1.Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). R. Sanchez-Pescador et al. Science 227, 484-492 (1985).\u003cbr\u003e2.Expression of heterologous gene proteins in yeast. S. Pichuantes, A.T. Nguyen and A. Franzusoff. In Protein Engineering: Principles and Practices. J.E. Clealand \u0026amp; C.S. Craik Editors, pp. 129-161 (1996).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- AB_PUBLISHED_USE_START --\u003e\n\u003csection class=\"ab-published-use ab-published-use-complete\"\u003e\n\u003ch3 id=\"ab-published-use-hi1a-730\"\u003ePublications using HI1A-730\u003c\/h3\u003e\n\u003cp\u003eThe following scientific publications report use of Austral Biologicals HIV-1 p55\/Gag antigen:\u003c\/p\u003e\n\u003col class=\"ab-publication-list ab-publication-list-complete\"\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1080\/15548627.2021.1972403\" rel=\"noopener\" target=\"_blank\"\u003eAutophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLoucif et al., Autophagy 18(6):1256-1273 (2022).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1080\/15548627.2021.1874134\" rel=\"noopener\" target=\"_blank\"\u003eLipophagy confers a key metabolic advantage that ensures protective CD8A T-cell responses against HIV-1\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eLoucif et al., Autophagy 17(11):3408-3423 (2021).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1008060\" rel=\"noopener\" target=\"_blank\"\u003eUSP18 is a significant driver of memory CD4 T-cell reduced viability caused by type I IFN signaling during primary HIV-1 infection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eDagenais-Lussier et al., PLoS Pathog 15(10):e1008060 (2019).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.00433-09\" rel=\"noopener\" target=\"_blank\"\u003eHuman immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eJones et al., J Virol 83(17):8722-8732 (2009).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.02550-07\" rel=\"noopener\" target=\"_blank\"\u003eVirus-specific interleukin-17-producing CD4+ T cells are detectable in early human immunodeficiency virus type 1 infection\u003c\/a\u003e. \u003cspan class=\"ab-publication-citation\"\u003eYue et al., J Virol 82(13):6767-6771 (2008).\u003c\/span\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003c!-- AB_PUBLISHED_USE_END --\u003e\n\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1A-730_Datasheet.pdf\" rel=\"noopener\" target=\"_blank\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876578094,"sku":"HI1A-730-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876610862,"sku":"HI1A-730-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1a-730-50ug.png?v=1788008599"},{"product_id":"hi1m-601","title":"Anti-HIV-1 envelope gp120 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eMouse monoclonal antibody obtained by immunization with highly purified gp120 (Clone 3G5\/2). It has been purified using Protein G.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1M-601_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876643630,"sku":"HI1M-601-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1m-601-100ug.png?v=1788008589"},{"product_id":"hi1m-711","title":"Anti-HIV-1 gag p17 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (clone 7G11\/E6)obtained by immunization with HIV-1 gag p17 antigen. The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1: 4,000 dilution) and Western Blot analysis (1: 6,000). It recognizes gag p17 (aa1 – aa133 of the gag polyprotein). It does not recognize the gag p24 sequence; therefore it can be used to differentiate the p24 region of the gag polyprotein.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Sanchez-Pescador, R. et al. (1985) Science 227, 484 – 492.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1M-711_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876676398,"sku":"HI1M-711-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1m-711-100ug.png?v=1788008612"},{"product_id":"hi1m-721","title":"HIV-1 gag p24 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (Clone 3I4\/I10) obtained by immunization with highly purified gag p24 antigen.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blots, detecting up to 500 pg of antigen using a 1:100 dilution. Since it can not react with the p17 region, it can be used to differenciate the p17 regions of the gag poliprotein.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Sanchez-Pescador, R. et al. (1985) Science 227, 484 –492.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1M-721_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876709166,"sku":"HI1M-721-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1m-721-100ug.png?v=1788008599"},{"product_id":"hi1m-731","title":"Anti- HIV-1 gag p55 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from a mouse monoclonal antibody (clone 4D1\/I12) obtained by immunization with HIV-1 gag polyprotein (55 kDa). The IgG fraction was purified using Protein G-Sepharose.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Stable for at least one year. Avoid repeated freezing and thawing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e This antibody can be used in ELISA assays (1: 30,000 dilution) and Western Blot analysis (1: 8,000). It is specific for the C-terminal region from aa370 – aa501 of gag p55. Since it does not recognize the p17 and p24 sequences, it can be used to differentiate the p17 and p24 regions of the gag polyprotein.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Sanchez-Pescador, R. et al. (1985) Science 227, 484 –492.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI1M-731_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518876741934,"sku":"HI1M-731-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi1m-731-100ug.png?v=1788008476"},{"product_id":"hi2a-800","title":"HIV-2 envelope 201 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase (SOD). It covers from Ala 548 to Lys 708 (D Val 686-Ala 704) of the envelope antigen of HIV-2 isolate UC1. It has been purified by differential extraction followed by gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 33 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 92% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in PBS, 0.1% SDS, 2mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodificiency virus Type 2 UC1 strain, S.W. Barnett, M. Quiroga, A. Werner, D. Dina and J.A. Levy. Journal of Virol. 67, 1006-1014 (1993).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2A-800_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876774702,"sku":"HI2A-800-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876807470,"sku":"HI2A-800-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2a-800-50ug.png?v=1788008599"},{"product_id":"hi2a-810","title":"HIV-2 envelope 300 antigen (RECOMBINANT)","description":"  \u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase (SOD). It covers from Tyr 457 to Asp 654 (( Gly 509-Ala 530) of the envelope protein of HIV-2 (ISYR isolate).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 37 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS; 0.1%SDS; 2mM EDTA (pH 7.5) (HI2A-810-4 = 100 µL\/ HI2A-810-5 = 200 µL)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. G. Franchini et al. Proc. Natl. Acad. Sci. US 86, 2433-2437 (1989).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2A-810_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876840238,"sku":"HI2A-810-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876873006,"sku":"HI2A-810-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2a-810-50ug.png?v=1788008476"},{"product_id":"hi2a-820","title":"HIV-2 envelope 310 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase. It covers from Tyr 457 to Asp 654 (D Gly 509-Ala 530) of the envelope protein of HIV-2 (ISYR isolate).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 37 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in PBS\/0.10% SDS\/2mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Molecular and biological characterization of replication competent human immunodefiiency type 2 (HIV-2) proviral clone. G. Francini et al. Proc. Natl. Acad. Sci. US, 86, 2433-2437 (1989).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2A-820_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876905774,"sku":"HI2A-820-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518876938542,"sku":"HI2A-820-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2a-820-50ug.png?v=1788008588"},{"product_id":"hi2a-830","title":"HIV-2 envelope 320 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase (SOD). It covers from Tyr 469 to Asp 666 (( Gly 521-Ala 542) of the envelope protein of HIV-2 (UC2 isolate).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 37 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS; 0.1%SDS; 2mM EDTA (pH 7.5) (HI2A-810-4 = 100 µL\/ HI2A-810-5 = 200 µL)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Molecular cloning of the HIV-2 strain that causes an AIDS-like disease in baboons. S.W. Barnett et al. J. Virology (1993), Vol. 67, 1006.\u003c\/li\u003e\n  \u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2A-830_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518876971310,"sku":"HI2A-830-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518877004078,"sku":"HI2A-830-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2a-830-50ug.png?v=1788008472"},{"product_id":"hi2a-850","title":"HIV-2 gag p26 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells. It covers from Val 132 to Leu 360 of the HIV-2 gag protein (UC-1 isolate) . It has been purified by ion exchange chromatography followed by gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 26 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1.0 mg\/mL in 50mM MES, 0.3M NaCl, 0.1% SDS, 1mM EDTA and 1mM EGTA (pH 5.9)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodificiency virus Type 2 UC1 strain, S.W. Barnett, M. Quiroga, A. Werner, D. Dina and J.A. Levy. Journal of Virol. 67, 1006-1014 (1993)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2A-850_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518877036846,"sku":"HI2A-850-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518877069614,"sku":"HI2A-850-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2a-850-50ug.png?v=1788008442"},{"product_id":"hi2m-801","title":"Anti-HIV-2 envelope 201 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HIV-2 env 201 antigen (Clone 3C5\/C3).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot (1\/100-1\/1000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.40 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2M-801_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518877102382,"sku":"HI2M-801-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2m-801-100ug.png?v=1788008442"},{"product_id":"hi2m-851","title":"Anti-HIV-2 gag p26 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HIV-2 gag p26 antigen (Clone 2C10\/E10).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.25 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2M-851_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518877135150,"sku":"HI2M-851-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2m-851-100ug.png?v=1788008464"},{"product_id":"hi2m-871","title":"Anti-HIV-2 peptide antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (Clone 7G8\/G12) obtained by immunization with highly purified HIV-2 envelope peptide.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Dot Blot analysis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HI2M-871_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518877167918,"sku":"HI2M-871-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-hi2m-871-100ug.png?v=1788008476"},{"product_id":"htia-900","title":"HTLV-I envelope 701 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase (SOD). It covers from Asp 166 to Arg 440 of the HTLV-I envelope protein (isolate ATK-1). It has been purified by differential extraction and gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 46 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS, 0.1% SDS, 1mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. M. Seiki, S. Hattori, Y. Hirayama and M. Yoshida. Proc. Natl. Acad. Sci. USA 80, 3618-3622 (1983).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIA-900_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518879101230,"sku":"HTIA-900-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518879133998,"sku":"HTIA-900-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htia-900-50ug.png?v=1788008404"},{"product_id":"htia-910","title":"HTLV-I envelope 702 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase (SOD). It covers from Asp 166 to Arg 440 (D Ala 313 to Ala 331) of the HTLV-I envelope protein (isolate ATK-1). The apparent MW is 44,500. It has been purified by differential extraction followed by gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS, 0.1% SDS, 1mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. M. Seiki, S. Hattori, Y. Hirayama and M. Yoshida. Proc. Natl. Acad. Sci. USA 80, 3618-3622 (1983).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIA-910_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518879166766,"sku":"HTIA-910-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518879199534,"sku":"HTIA-910-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htia-910-50ug.png?v=1788008402"},{"product_id":"htia-980","title":"HTLV-I gag p19 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a protein fusion with human superoxide dismutase (SOD). It covers from Met 1 to Leu 130 of the HTLV-I gag protein (isolate ATK-1). The apparent MW is 30,700. It has been purified by ionic exchange followed by gel filtration chromatography.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in PBS, 1mM EDTA (pH 7.4)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. M. Seiki, S. Hattori, Y. Hirayama and M. Yoshida. Proc. Natl. Acad. Sci. USA 80, 3618-3622 (1983).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIA-980_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518879232302,"sku":"HTIA-980-4","price":295.0,"currency_code":"USD","in_stock":false},{"title":"100 µg","offer_id":52518879265070,"sku":"HTIA-980-5","price":495.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htia-980-50ug.png?v=1788008392"},{"product_id":"htia-990","title":"HTLV-I gag p24 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells. It covers from Pro 131 to Leu 344 of the HTLV-I gag protein (isolate ATK-1) . It has been purified by ion exchange chromatography followed by gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 24 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 95% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in PBS, 0.1% SDS, 2 mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. M. Seiki, S. Hattori, Y. Hirayama and M. Yoshida. Proc. Natl. Acad. Sci. USA 80, 3618-3622 (1983).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIA-990_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518879297838,"sku":"HTIA-990-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518879330606,"sku":"HTIA-990-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htia-990-50ug.png?v=1788008388"},{"product_id":"htiia-1170","title":"HTLV-II envelope 802 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells as a fusion protein with human superoxide dismutase (SOD). It covers from Ala 309 to Gln 440 of the HTLV-II envelope protein (lambda H6.0 isolate). It has been purified by differential extractions followed by gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 30 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in PBS, 0.1% SDS, 1mM EDTA (pH 7.4)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: An open reading frame of the protease gene. K. Shimotohno, Y. Takahasi, N. Shimizu, T. Gojobori, D. Golde, I. Chen, M. Niwa and T. Sugimura.Proc. Natl. Acad. Sci. USA 82, 2 01-3105 (1985).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIIA-1170_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518879396142,"sku":"HTIIA-1170-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518879428910,"sku":"HTIIA-1170-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htiia-1170-50ug.png?v=1788008387"},{"product_id":"htiia-1190","title":"HTLV-II gag p24 antigen (RECOMBINANT)","description":"\u003cp\u003eProtein produced in genetically engineered yeast cells. It covers from Pro 137 to Leu 350 of the HTLV-II gag protein (lambda H6.0 isolate). It has been purified by ion-exchange chromatography followed by gel filtration.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 24 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 90% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 1 mg\/mL in PBS, 0.1% SDS, 2mM EDTA (pH 7.5)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: An open reading frame of the protease gene. K. Shimotohno, Y. Takahasi, N. Shimizu, T. Gojobori, D. Golde, I. Chen, M. Niwa and T. Sugimura. 2 Proc. Natl. Acad. Sci. USA 82, 3101-3105 (1985).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIIA-1190_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"50 µg","offer_id":52518879461678,"sku":"HTIIA-1190-4","price":295.0,"currency_code":"USD","in_stock":true},{"title":"100 µg","offer_id":52518879494446,"sku":"HTIIA-1190-5","price":495.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htiia-1190-50ug.png?v=1788008391"},{"product_id":"htiim-1161","title":"Anti-HTLV-II envelope 801 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HTLV-II envelope 801 antigen (Clone 2F8\/E4).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.10 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIIM-1161_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879527214,"sku":"HTIIM-1161-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htiim-1161-100ug.png?v=1788008404"},{"product_id":"htiim-1171","title":"Anti-HTLV-II envelope 802 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HTLV-II envelope 802 antigen (Clone 8F2\/G8).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIIM-1171_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879559982,"sku":"HTIIM-1171-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htiim-1171-100ug.png?v=1788008391"},{"product_id":"htiim-1191","title":"Anti-HTLV-II gag p24 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HTLV-II gag p24 antigen (7D10\/I3).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.10 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIIM-1191_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879592750,"sku":"HTIIM-1191-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htiim-1191-100ug.png?v=1788008391"},{"product_id":"htiipe-1210","title":"HTLV-II envelope peptide 1","description":"\u003cp\u003eChemically synthesized peptide covering from Pro 164 to Lys 205 of the HTLV-II envelope protein (lambda H6.0 isolate).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 98% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: An open reading frame of the protease gene. K. Shimotohno, Y. Takahasi, N. Shimizu, T. Gojobori, D. Golde, I. Chen, M. Niwa and T. Sugimura. Proc. Natl. Acad. Sci. USA 82, 3101-3105 (1985).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIIPE-1210_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879625518,"sku":"HTIIPE-1210-5","price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htiipe-1210-100ug.png?v=1788008403"},{"product_id":"htiipem-1211","title":"Anti-HTLV-II envelope peptide 1 IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody (Clone 2E11\/I6) obtained by immunization with chemically synthesized HTLV-II envelope peptide 1.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.40 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIIPEM-1211_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879658286,"sku":"HTIIPEM-1211-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htiipem-1211-100ug.png?v=1788008346"},{"product_id":"htim-901","title":"Anti-HTLV-I envelope 701 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HTLV-I envelope 701 antigen (Clone 6C7\/E9).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot (1\/100-1\/1000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIM-901_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879691054,"sku":"HTIM-901-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htim-901-100ug.png?v=1788008346"},{"product_id":"htim-911","title":"Anti-HTLV-I envelope 702 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HTLV-I envelope 702 antigen (Clone 3H9\/D6).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot (1\/100-1\/1000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.25 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIM-911_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879723822,"sku":"HTIM-911-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htim-911-100ug.png?v=1788008380"},{"product_id":"htim-981","title":"Anti-HTLV-I gag p19 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HTLV-I gag p19 antigen (Clone 6E10\/B8)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot (1\/100-1\/1000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.10 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIM-981_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879756590,"sku":"HTIM-981-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htim-981-100ug.png?v=1788008380"},{"product_id":"htim-991","title":"Anti-HTLV-I gag p24 antigen IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with highly purified HTLV-I gag p24 antigen (Clone 4D7\/H5)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot (1\/100-1\/1000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.50 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIM-991_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879789358,"sku":"HTIM-991-5","price":425.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htim-991-100ug.png?v=1788008381"},{"product_id":"htipe-1070","title":"HTLV-I E1 peptide","description":"\u003cp\u003eChemically synthesized peptide covering from Ser 162 to Lys 209 of the HTLV-I envelope protein (ATK-1 isolate)\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e Over 98% pure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year +4°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized powder. Free of salt.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReferences:\u003c\/strong\u003e Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. M. Seiki, S. Hattori, Y. Hirayama and M. Yoshida. Proc. Natl. Acad. Sci. USA 80, 3618-3622 (1983).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIPE-1070_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879822126,"sku":"HTIPE-1070-5","price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htipe-1070-100ug.png?v=1788008380"},{"product_id":"htipem-1071","title":"Anti-HTLV-I E1 peptide IgG fraction (monoclonal)","description":"\u003cp\u003eIgG fraction from mouse monoclonal antibody obtained by immunization with HTLV-I E1 peptide (Clone 5B2\/E8).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e At least 1 year at -20°C.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Reacts in ELISA and Western blot (1\/100-1\/1000 dilution).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormulation:\u003c\/strong\u003e Solution at 0.25 mg\/mL in 0.1M Tris-HCl (pH 7.5)\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"ab-datasheet-link\"\u003e\u003ca href=\"https:\/\/helix-chartreuse-ypja.squarespace.com\/s\/Austral_Biologicals_HTIPEM-1071_Datasheet.pdf\" target=\"_blank\" rel=\"noopener\"\u003e\u003cstrong\u003eDownload technical datasheet (PDF)\u003c\/strong\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"Austral Biologicals","offers":[{"title":"100 µg","offer_id":52518879854894,"sku":"HTIPEM-1071-5","price":395.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1006\/2846\/3918\/files\/austral-biologicals-htipem-1071-100ug.png?v=1788008358"}],"url":"https:\/\/www.australbiologicals.com\/collections\/retroviruses-hiv-htlv-herv.oembed","provider":"Austral Biologicals","version":"1.0","type":"link"}